Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL), known for its advanced therapies in sports medicine and severe burn care, announced that President and CEO Nick Colangelo will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on March 22, 2022, at 11:00 a.m. Central Time. A webcast of the presentation will be accessible via the Investor Relations section of Vericel's website.

Vericel markets two primary cell therapy products: MACI®, for knee cartilage repair, and Epicel®, a skin replacement for severe burns. Additionally, the company holds rights to NexoBrid®, a product for burn debridement.

Argus Session date unavailable

+3.50% session move Open Argus

Details

News Market Reaction – VCEL

The recorded move for VCEL in the trading session of this news was +3.50%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskeletal Conference in Chicago, IL on Tuesday, March 22^nd at 11:00 a.m. Central Time.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Nick Colangelo's presentation at the Canaccord Genuity Musculoskeletal Conference?

Nick Colangelo will present on March 22, 2022, at 11:00 a.m. Central Time.

Where can I watch Vericel's conference presentation?

The presentation will be available via webcast on the Investor Relations section of Vericel's website.

What products does Vericel Corporation offer?

Vericel offers MACI® for knee cartilage repair and Epicel® for severe burn treatment.

What is NexoBrid® and its relevance to Vericel?

NexoBrid® is a biological orphan product for severe thermal burn debridement for which Vericel holds an exclusive license in North America.